

# Argentina

Population 2016

44 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.6 (0.58–0.63)	1.4 (1.3–1.4)
Mortality (HIV+TB only)	0.064 (0.031–0.11)	0.15 (0.07–0.25)
Incidence (includes HIV+TB)	11 (9.2–12)	24 (21–28)
Incidence (HIV+TB only)	0.59 (0.38–0.85)	1.4 (0.87–1.9)
Incidence (MDR/RR-TB)**	0.44 (0.29–0.58)	0.99 (0.66–1.3)

## Estimated TB incidence by age and sex (thousands)\*, 2016

	0-14 years	> 14 years	Total
Females	0.57 (0.49–0.66)	3.5 (3–4)	4.1 (3.5–4.6)
Males	0.59 (0.51–0.68)	6 (5.1–6.9)	6.6 (5.6–7.6)
Total	1.2 (1–1.3)	9.5 (8.1–11)	11 (9.2–12)

## TB case notifications, 2016

Total cases notified	10 592
Total new and relapse	10 023
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	19%
- % pulmonary	85%
- % bacteriologically confirmed among pulmonary	65%

## Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2016	94% (82–110)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.06 (0.05–0.07)

## TB/HIV care in new and relapse TB patients, 2016

	Number	(%)
Patients with known HIV-status who are HIV-positive	592	31%
- on antiretroviral therapy	167	28%

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			370 (240–500)
Estimated % of TB cases with MDR/RR-TB	2.3% (1.1–3.6)	18% (9.5–27)	
% notified tested for rifampicin resistance			
MDR/RR-TB cases tested for resistance to second-line drugs			112
Laboratory-confirmed cases		MDR/RR-TB: 114, XDR-TB: 2	
Patients started on treatment ****		MDR/RR-TB: 114, XDR-TB:	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2015	47%	9 854
Previously treated cases, excluding relapse, registered in 2015	38%	956
HIV-positive TB cases registered in 2015	28%	655
MDR/RR-TB cases started on second-line treatment in 2014	26%	121
XDR-TB cases started on second-line treatment in 2014	40%	5

## TB preventive treatment, 2016

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

## TB financing, 2017

National TB budget (US\$ millions)	4.6
Funding source: 100% domestic, 0% international, 0% unfunded	

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


# Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

## Notified cases by age group and sex, 2016




## Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB

## Total budget (US\$ millions)



— Unfunded  
— Funded internationally  
— Funded domestically